8:01 AM
 | 
Jun 29, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AZ and Merck's Lynparza meets in Phase III for first-line ovarian cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) said Lynparza olaparib as a first-line maintenance therapy improved progression-free survival (PFS) vs. placebo in patients with BRCA-mutated advanced ovarian cancer, meeting the primary endpoint of the Phase III SOLO-1 trial.

Lynparza is the...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >